Program
pralatrexate
Also written as “Pralatrexate Injection”, “Pralatrexate” and “Folotyn”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, Cutaneous · Hematologic Neoplasms · Lymphoma, B-Cell, led by 3 companies.
Drug pagePralatrexate: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aurobindo Pharmaits history only | 122 open or running | phase 3since Sep 19, 2023 | Aug 14, 2006 | Feb 2027phase 1 · NCT07036133 |
| Zydus Lifesciences | 40 open or running | phase 3since Aug 18, 2011 | Jan 24, 2003 | none ahead |
| Mundipharmaits history only | 30 open or running | phase 4since May 5, 2017 | Dec 4, 2013 | none ahead |
Also a collaborator on its studies: Axis Clinicals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Zydus Lifesciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2003First study: phase 2 study in LymphomaFirst studyNCT00052442 · 72 enrolled · United States
- Jan 22, 2008Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00606502 · 201 enrolled · United States, Argentina, Brazil and more
- Oct 19, 2009Phase 2 study in Lymphoma, B-CellNCT00998946 · 29 enrolled · United States
- Aug 18, 2011Phase 3 study in Lymphoma, T-Cell, PeripheralNCT01420679 · 21 enrolled · United States, Australia, Belgium and more
TargetBeta
“A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities”NCIt, by rule
“Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Studies
All 4 Zydus Lifesciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01420679Lymphoma, T-Cell, Peripheral · United States, Australia, Belgium and more | 3 | Terminated | Dec 2017 | 21 |
| NCT00998946Lymphoma, B-Cell · United States | 2 | Completed | Aug 2012 | 29 |
| NCT00606502Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 2 | Completed | Jun 24, 2010 | 201 |
| NCT00052442Lymphoma · United States | 2 | Completed | Mar 2009 | 72 |
How it is read
Names in the registry
- “Pralatrexate Injection”, 9 entries
- “Pralatrexate”, 4 entries
- “pralatrexate”, 2 entries
- “Folotyn”, 2 entries
- “Folotyn and Leucovorin”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 8 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Lymphoma, T-Cell, Cutaneous, 2 studies
- Hematologic Neoplasms, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.